Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis

Leah M. Cook, Jeremy S. Frieling, Niveditha Nerlakanti, Jeremy J. McGuire, Paul A. Stewart, Karen L. Burger, John L. Cleveland, Conor C. Lynch

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Bone metastatic prostate cancer provokes extensive osteogenesis by driving the recruitment and osteoblastic differentiation of mesenchymal stromal cells (MSCs). The resulting lesions greatly contribute to patient morbidity and mortality, underscoring the need for defining how prostate metastases subvert the MSC–osteoblast differentiation program. To gain insights into this process we profiled the effects of co-culture of primary MSCs with validated bone metastatic prostate cancer cell line models. These analyses revealed a cast of shared differentially induced genes in MSC, including betaglycan, a co-receptor for TGFβ. Betaglycan has not been studied in the context of bone metastatic disease previously. Here we report that loss of betaglycan in MSC is sufficient to augment TGFβ signaling, proliferation and migration, and completely blocks the MSC–osteoblast differentiation program. Further, betaglycan was revealed as necessary for prostate cancer-induced osteogenesis in vivo. Mechanistically, gene expression analysis revealed betaglycan controls the expression of a large repertoire of genes in MSCs, and that betaglycan loss provokes >60-fold increase in the expression of Wnt5a that plays important roles in stemness. In accord with the increased Wnt5a levels, there was a marked induction of canonical Wnt signaling in betaglycan ablated MSCs, and the addition of recombinant Wnt5a to MSCs was sufficient to impair osteogenic differentiation. Finally, the addition of Wnt5a neutralizing antibody was sufficient to induce the expression of osteogenic genes in betaglycan-ablated MSCs. Collectively, these findings suggest a betaglycan–Wnt5a circuit represents an attractive vulnerability to ameliorate prostate cancer-induced osteogenesis.

Original languageEnglish (US)
Pages (from-to)6959-6969
Number of pages11
JournalOncogene
Volume38
Issue number44
DOIs
StatePublished - Oct 31 2019

Fingerprint

Mesenchymal Stromal Cells
Osteogenesis
Prostatic Neoplasms
Gene Expression
Bone and Bones
betaglycan
Bone Diseases
Coculture Techniques
Neutralizing Antibodies
Genes
Prostate
Neoplasm Metastasis
Morbidity
Cell Line
Mortality

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Cook, L. M., Frieling, J. S., Nerlakanti, N., McGuire, J. J., Stewart, P. A., Burger, K. L., ... Lynch, C. C. (2019). Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis. Oncogene, 38(44), 6959-6969. https://doi.org/10.1038/s41388-019-0913-4

Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis. / Cook, Leah M.; Frieling, Jeremy S.; Nerlakanti, Niveditha; McGuire, Jeremy J.; Stewart, Paul A.; Burger, Karen L.; Cleveland, John L.; Lynch, Conor C.

In: Oncogene, Vol. 38, No. 44, 31.10.2019, p. 6959-6969.

Research output: Contribution to journalArticle

Cook, LM, Frieling, JS, Nerlakanti, N, McGuire, JJ, Stewart, PA, Burger, KL, Cleveland, JL & Lynch, CC 2019, 'Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis', Oncogene, vol. 38, no. 44, pp. 6959-6969. https://doi.org/10.1038/s41388-019-0913-4
Cook, Leah M. ; Frieling, Jeremy S. ; Nerlakanti, Niveditha ; McGuire, Jeremy J. ; Stewart, Paul A. ; Burger, Karen L. ; Cleveland, John L. ; Lynch, Conor C. / Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis. In: Oncogene. 2019 ; Vol. 38, No. 44. pp. 6959-6969.
@article{9b0c420607184af3818bd1eda8ae265c,
title = "Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis",
abstract = "Bone metastatic prostate cancer provokes extensive osteogenesis by driving the recruitment and osteoblastic differentiation of mesenchymal stromal cells (MSCs). The resulting lesions greatly contribute to patient morbidity and mortality, underscoring the need for defining how prostate metastases subvert the MSC–osteoblast differentiation program. To gain insights into this process we profiled the effects of co-culture of primary MSCs with validated bone metastatic prostate cancer cell line models. These analyses revealed a cast of shared differentially induced genes in MSC, including betaglycan, a co-receptor for TGFβ. Betaglycan has not been studied in the context of bone metastatic disease previously. Here we report that loss of betaglycan in MSC is sufficient to augment TGFβ signaling, proliferation and migration, and completely blocks the MSC–osteoblast differentiation program. Further, betaglycan was revealed as necessary for prostate cancer-induced osteogenesis in vivo. Mechanistically, gene expression analysis revealed betaglycan controls the expression of a large repertoire of genes in MSCs, and that betaglycan loss provokes >60-fold increase in the expression of Wnt5a that plays important roles in stemness. In accord with the increased Wnt5a levels, there was a marked induction of canonical Wnt signaling in betaglycan ablated MSCs, and the addition of recombinant Wnt5a to MSCs was sufficient to impair osteogenic differentiation. Finally, the addition of Wnt5a neutralizing antibody was sufficient to induce the expression of osteogenic genes in betaglycan-ablated MSCs. Collectively, these findings suggest a betaglycan–Wnt5a circuit represents an attractive vulnerability to ameliorate prostate cancer-induced osteogenesis.",
author = "Cook, {Leah M.} and Frieling, {Jeremy S.} and Niveditha Nerlakanti and McGuire, {Jeremy J.} and Stewart, {Paul A.} and Burger, {Karen L.} and Cleveland, {John L.} and Lynch, {Conor C.}",
year = "2019",
month = "10",
day = "31",
doi = "10.1038/s41388-019-0913-4",
language = "English (US)",
volume = "38",
pages = "6959--6969",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "44",

}

TY - JOUR

T1 - Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis

AU - Cook, Leah M.

AU - Frieling, Jeremy S.

AU - Nerlakanti, Niveditha

AU - McGuire, Jeremy J.

AU - Stewart, Paul A.

AU - Burger, Karen L.

AU - Cleveland, John L.

AU - Lynch, Conor C.

PY - 2019/10/31

Y1 - 2019/10/31

N2 - Bone metastatic prostate cancer provokes extensive osteogenesis by driving the recruitment and osteoblastic differentiation of mesenchymal stromal cells (MSCs). The resulting lesions greatly contribute to patient morbidity and mortality, underscoring the need for defining how prostate metastases subvert the MSC–osteoblast differentiation program. To gain insights into this process we profiled the effects of co-culture of primary MSCs with validated bone metastatic prostate cancer cell line models. These analyses revealed a cast of shared differentially induced genes in MSC, including betaglycan, a co-receptor for TGFβ. Betaglycan has not been studied in the context of bone metastatic disease previously. Here we report that loss of betaglycan in MSC is sufficient to augment TGFβ signaling, proliferation and migration, and completely blocks the MSC–osteoblast differentiation program. Further, betaglycan was revealed as necessary for prostate cancer-induced osteogenesis in vivo. Mechanistically, gene expression analysis revealed betaglycan controls the expression of a large repertoire of genes in MSCs, and that betaglycan loss provokes >60-fold increase in the expression of Wnt5a that plays important roles in stemness. In accord with the increased Wnt5a levels, there was a marked induction of canonical Wnt signaling in betaglycan ablated MSCs, and the addition of recombinant Wnt5a to MSCs was sufficient to impair osteogenic differentiation. Finally, the addition of Wnt5a neutralizing antibody was sufficient to induce the expression of osteogenic genes in betaglycan-ablated MSCs. Collectively, these findings suggest a betaglycan–Wnt5a circuit represents an attractive vulnerability to ameliorate prostate cancer-induced osteogenesis.

AB - Bone metastatic prostate cancer provokes extensive osteogenesis by driving the recruitment and osteoblastic differentiation of mesenchymal stromal cells (MSCs). The resulting lesions greatly contribute to patient morbidity and mortality, underscoring the need for defining how prostate metastases subvert the MSC–osteoblast differentiation program. To gain insights into this process we profiled the effects of co-culture of primary MSCs with validated bone metastatic prostate cancer cell line models. These analyses revealed a cast of shared differentially induced genes in MSC, including betaglycan, a co-receptor for TGFβ. Betaglycan has not been studied in the context of bone metastatic disease previously. Here we report that loss of betaglycan in MSC is sufficient to augment TGFβ signaling, proliferation and migration, and completely blocks the MSC–osteoblast differentiation program. Further, betaglycan was revealed as necessary for prostate cancer-induced osteogenesis in vivo. Mechanistically, gene expression analysis revealed betaglycan controls the expression of a large repertoire of genes in MSCs, and that betaglycan loss provokes >60-fold increase in the expression of Wnt5a that plays important roles in stemness. In accord with the increased Wnt5a levels, there was a marked induction of canonical Wnt signaling in betaglycan ablated MSCs, and the addition of recombinant Wnt5a to MSCs was sufficient to impair osteogenic differentiation. Finally, the addition of Wnt5a neutralizing antibody was sufficient to induce the expression of osteogenic genes in betaglycan-ablated MSCs. Collectively, these findings suggest a betaglycan–Wnt5a circuit represents an attractive vulnerability to ameliorate prostate cancer-induced osteogenesis.

UR - http://www.scopus.com/inward/record.url?scp=85070856986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070856986&partnerID=8YFLogxK

U2 - 10.1038/s41388-019-0913-4

DO - 10.1038/s41388-019-0913-4

M3 - Article

C2 - 31409900

AN - SCOPUS:85070856986

VL - 38

SP - 6959

EP - 6969

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 44

ER -